FDA Approvals - Neuralstem's NSI-189 trial in major depressive disorder receives FDA approval
Neuralstem's NSI-189 trial in major depressive disorder receives FDA approval to advance to Phase Ib
( Neuralstem, Inc. ) Neuralstem's NSI-189 Neuroregenerative drug advances to Phase Ib in a major depressive disorder trial.